BR112012004304A2 - quinolinas condensadas como moduladores de proteína cinase. - Google Patents

quinolinas condensadas como moduladores de proteína cinase.

Info

Publication number
BR112012004304A2
BR112012004304A2 BR112012004304A BR112012004304A BR112012004304A2 BR 112012004304 A2 BR112012004304 A2 BR 112012004304A2 BR 112012004304 A BR112012004304 A BR 112012004304A BR 112012004304 A BR112012004304 A BR 112012004304A BR 112012004304 A2 BR112012004304 A2 BR 112012004304A2
Authority
BR
Brazil
Prior art keywords
quinolines
condensed
protein kinase
kinase modulators
modulators
Prior art date
Application number
BR112012004304A
Other languages
English (en)
Inventor
Collin F Regan
David M Ryckman
Fabrice Pierre
Mustapha Haddach
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BR112012004304A2 publication Critical patent/BR112012004304A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012004304A 2009-08-26 2010-08-26 quinolinas condensadas como moduladores de proteína cinase. BR112012004304A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23722709P 2009-08-26 2009-08-26
US28931709P 2009-12-22 2009-12-22
PCT/US2010/046760 WO2011025859A1 (en) 2009-08-26 2010-08-26 Condensed quinolines as protein kinase modulators

Publications (1)

Publication Number Publication Date
BR112012004304A2 true BR112012004304A2 (pt) 2016-03-15

Family

ID=42983433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004304A BR112012004304A2 (pt) 2009-08-26 2010-08-26 quinolinas condensadas como moduladores de proteína cinase.

Country Status (13)

Country Link
US (1) US20110065698A1 (pt)
EP (1) EP2470544A1 (pt)
JP (1) JP2013503178A (pt)
KR (1) KR20120059571A (pt)
CN (1) CN102596969A (pt)
AU (1) AU2010286691A1 (pt)
BR (1) BR112012004304A2 (pt)
CA (1) CA2771890A1 (pt)
IL (1) IL218280A0 (pt)
IN (1) IN2012DN02596A (pt)
MX (1) MX2012002426A (pt)
SG (1) SG178552A1 (pt)
WO (1) WO2011025859A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
JP6554037B2 (ja) 2013-01-15 2019-07-31 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
AU2014308703A1 (en) 2013-08-23 2016-03-24 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
CN111031799A (zh) * 2017-07-03 2020-04-17 拜耳作物科学股份公司 新的取代的异噻唑并吡啶酮、其制备方法及其用作除草剂和/或植物生长调节剂的用途
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
GB202213163D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) * 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP2003509501A (ja) 1999-09-23 2003-03-11 アストラゼネカ・アクチエボラーグ 治療薬キナゾリン化合物
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
CN101160307A (zh) 2005-02-17 2008-04-09 Amr科技公司 用于治疗cinv和ibs-d的苯并噁唑甲酰胺
EP2061765B1 (en) * 2006-09-01 2014-10-22 Senhwa Biosciences, Inc. Serine-threonine protein kinase and PARP modulators
CN102036561A (zh) * 2008-02-29 2011-04-27 赛林药物股份有限公司 蛋白激酶调节剂
EP2324029A4 (en) * 2008-09-10 2011-09-14 Kalypsys Inc HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
JP2013503178A (ja) 2013-01-31
IN2012DN02596A (pt) 2015-08-28
US20110065698A1 (en) 2011-03-17
IL218280A0 (en) 2012-04-30
KR20120059571A (ko) 2012-06-08
EP2470544A1 (en) 2012-07-04
AU2010286691A1 (en) 2012-04-19
CA2771890A1 (en) 2011-03-03
WO2011025859A1 (en) 2011-03-03
CN102596969A (zh) 2012-07-18
SG178552A1 (en) 2012-03-29
MX2012002426A (es) 2012-06-27

Similar Documents

Publication Publication Date Title
BR112012004304A2 (pt) quinolinas condensadas como moduladores de proteína cinase.
BR112012004718A2 (pt) compostos como moduladores de tirosina quinase
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
FR2947261B1 (fr) Zircone frittee coloree.
BR112012010640A2 (pt) novos moduladores de quinase
BRPI1013760A2 (pt) compostos anticâncer de amino pirimidina.
BRPI1013688A2 (pt) proteínas de ligação de il-17.
BRPI1011694A2 (pt) similadores de categoria
BRPI1011965A2 (pt) estrutura de entressola.
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
BRPI0919898A2 (pt) 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
BR112013013548A2 (pt) proteína de fusão anticancerígena
BRPI1014388A2 (pt) preparação de sólido.
BR112012001305A2 (pt) protetor de pavimentação.
BRPI1016192A2 (pt) derivados de soxazol.
IT1396487B1 (it) Convogliatore.
BRPI1014897A2 (pt) dispositivo de suspensão.
BRPI1009519A2 (pt) 3-amino-2-mercaptoquinolina substituída como modulador de kcnq2/3.
BRPI1013799A2 (pt) eletrodos de desfibrilação.
BRPI1013966A2 (pt) microensaio de esterilidade rápida.
IT1397694B1 (it) Puntale per attacchi da sci-alpinismo.
BR112012000565A2 (pt) ensaio de vírus.
BRPI0924638A2 (pt) ativação de função.
BR112012014495A2 (pt) cosmético de autonivelamento.
BRPI1009515A2 (pt) Complexos de proteínas/glicosinolatos eletrostáticos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]